Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063 | EVP, Business Development | August 17, 2026 | August 19, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TEVA PHARMACEUTICAL INDUSTRIES LTD
Report date August 17, 2026 · Filed August 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 25,591 |
Reported balance
After 2026-08-17 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-17 · Sale · Disposed 18,600 · Balance 25,591 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2026. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.57 to $36.61, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2026.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.57 to $36.61, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 17, 2026 Filed Aug 19, 2026 20:00 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 18,600 | $36.57 | $680,291.28 |
DisclosureSEC source: 0001193125-26-356853 · ownership.xml · nonDerivative · entry 1 Lippman Evan · CIK 0002062834 · EVP, Business Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,591 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2026. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.57 to $36.61, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 14, 2026 Filed May 18, 2026 20:02 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 74,008 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-228876 · ownership.xml · derivative · entry 6 Lippman Evan · CIK 0002062834 · EVP, Business Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,008 Underlying: Ordinary Shares · 74,008 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F7 · derivative.exercise_date: Restricted share units were granted on May 14, 2025, with 74,008 vested on May 14, 2026, and 37,004 vesting on each of May 14, 2027 and May 14, 2028. F7 · derivative.expiration_date: Restricted share units were granted on May 14, 2025, with 74,008 vested on May 14, 2026, and 37,004 vesting on each of May 14, 2027 and May 14, 2028. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| May 14, 2026 Filed May 18, 2026 20:02 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 11,841 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-228876 · ownership.xml · derivative · entry 5 Lippman Evan · CIK 0002062834 · EVP, Business Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,524 Underlying: Ordinary Shares · 11,841 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on May 14, 2025, with 11,841 vested on May 14, 2026, 11,841 vesting on each of May 14, 2027 and May 14, 2028, and 11,842 vesting on May 14, 2029. F6 · derivative.expiration_date: Restricted share units were granted on May 14, 2025, with 11,841 vested on May 14, 2026, 11,841 vesting on each of May 14, 2027 and May 14, 2028, and 11,842 vesting on May 14, 2029. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| May 14, 2026 Filed May 18, 2026 20:02 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 35,912 | $35.58 | $1,277,899.79 |
DisclosureSEC source: 0001193125-26-228876 · ownership.xml · nonDerivative · entry 4 Lippman Evan · CIK 0002062834 · EVP, Business Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,191 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.38 to $35.685, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 14, 2026 Filed May 18, 2026 20:02 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 74,008 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-228876 · ownership.xml · nonDerivative · entry 3 Lippman Evan · CIK 0002062834 · EVP, Business Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 80,103 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| May 14, 2026 Filed May 18, 2026 20:02 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 5,746 | $35.58 | $204,466.81 |
DisclosureSEC source: 0001193125-26-228876 · ownership.xml · nonDerivative · entry 2 Lippman Evan · CIK 0002062834 · EVP, Business Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,095 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.38 to $35.685, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 14, 2026 Filed May 18, 2026 20:02 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 11,841 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-228876 · ownership.xml · nonDerivative · entry 1 Lippman Evan · CIK 0002062834 · EVP, Business Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,841 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:11 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 27,347 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-096530 · ownership.xml · derivative · entry 1 Lippman Evan · CIK 0002062834 · EVP, Business Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,347 Underlying: Ordinary Shares · 27,347 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on March 4, 2026, with 6,836 vesting on each of March 4, 2027, March 4, 2028 and March 4, 2029, and 6,839 vesting on March 4, 2030. F2 · derivative.expiration_date: Restricted share units were granted on March 4, 2026, with 6,836 vesting on each of March 4, 2027, March 4, 2028 and March 4, 2029, and 6,839 vesting on March 4, 2030. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| May 14, 2025 Filed May 19, 2025 20:00 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 148,016 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-074286 · ownership.xml · derivative · entry 2 Lippman Evan · CIK 0002062834 · EVP, Business Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,016 Underlying: Ordinary Shares · 148,016 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on May 14, 2025 with 74,008 vesting on May 14, 2026, and 37,004 vesting on each of May 14, 2027 and May 14, 2028. F4 · derivative.expiration_date: Restricted share units were granted on May 14, 2025 with 74,008 vesting on May 14, 2026, and 37,004 vesting on each of May 14, 2027 and May 14, 2028. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| May 14, 2025 Filed May 19, 2025 20:00 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 47,365 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-074286 · ownership.xml · derivative · entry 1 Lippman Evan · CIK 0002062834 · EVP, Business Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,365 Underlying: Ordinary Shares · 47,365 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on May 14, 2025 with 11,841 vesting on each of May 14, 2026, May 14, 2027 and May 14, 2028, and 11,842 vesting on May 14, 2029. F2 · derivative.expiration_date: Restricted share units were granted on May 14, 2025 with 11,841 vesting on each of May 14, 2026, May 14, 2027 and May 14, 2028, and 11,842 vesting on May 14, 2029. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.